CSIMarket
 


Idexx Laboratories Inc  (IDXX)
Other Ticker:  
 

Cumulative Idexx Laboratories Inc's Quick Ratio for Trailing Twelve Months Period

IDXX's Quick Ratio for Trailing Twelve Months Period and Cash & cash equivalent, Current Liabilities growth


Select the Comparisons : Select the Ratio:

IDXX Quick Ratio for Trailing Twelve Months Period

(Dec 31 2023)
IV. Quarter
(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
Y / Y Current Liabilities Growth -23 % -15.57 % -21.49 % 14.53 % 61.84 %
Y / Y Cash & cash equivalent Growth 303.33 % 234.45 % 16.16 % -45.57 % -22.09 %
Quick Ratio for Trailing Twelve Months Period 0.27 0.17 0.11 0.1 0.12
Total Ranking # 1515 # 2842 # 3330 # 3598 # 4063
Seq. Current Liabilities Growth -1.92 % 9.77 % -17.06 % -13.77 % 7.54 %
Seq. Cash & cash equivalent Growth 36.85 % 149.7 % 19.28 % -1.05 % 13.48 %


Quick Ratio for Trailing Twelve Months Period Comment for 12 Months ending at Dec 31 2023
On the trailing twelve months basis Idexx Laboratories Inc Cash & cash equivalent average more than doubled by 303.33% in IV. Quarter year on year, while Current Liabilities decreased to $ 952 millions, this led to increase in in Idexx Laboratories Inc's Quick Ratio for Trailing Twelve Months Period to 0.27, Quick Ratio for Trailing Twelve Months Period remained below Idexx Laboratories Inc average.
Quick Ratio for Trailing Twelve Months Period is the average cumulative value over the last four quarters.

Among companies operatig within In Vitro & In Vivo Diagnostic Substances industry 4 other companies have achieved higher Quick Ratio for Trailing Twelve Months Period than Idexx Laboratories Inc. While overall ranking remained unchanged compare to previous quarter at no. .

What is Quick Ratio?
Learn more about IDXX
Quick Ratio IDXX in the most recent quarter
Quick Ratio for Trailing Twelve Months Period Company Ranking
Within: No.
Industry # 5
Sector # 369
S&P 500 # 1181


Quick Ratio for Trailing Twelve Months Period Statistics
High Average Low
0.52 0.34 0.09
(Sep. 30, 2014)  




Companies with similar average Quick Ratio for Trailing Twelve Months Period for 12 months ending Dec 31 2023, within In Vitro & In Vivo Diagnostic Substances Industry Quick Ratio for Trailing Twelve Months Period
Nymox Pharmaceutical Corporation  0.68 
Myriad Genetics Inc   0.65 
Volitionrx Limited  0.62 
Trinity Biotech Plc  0.49 
Quotient Limited  0.40 
Quidelortho Corp  0.34 
Idexx Laboratories Inc  0.24 
Navidea Biopharmaceuticals Inc   0.22 
Burzynski Research Institute Inc  0.06 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com